Symbiotec Pharmalab
Ticker > Company >

Symbiotec Pharmalab share price

Symbiotec Pharmalab Ltd.

  4.02 K   0   0 NSE: SYMBIOTEC BSE: 544889 SECTOR: Pharmaceuticals & Drugs

1097.70
+109.70 (11.10%)
NSE: Today, 04:09 PM

Buy on Angel One

Price Summary

Today's High

₹ 1180

Today's Low

₹ 934.2

52 Week High

₹ 0

52 Week Low

₹ 0

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 7053.39 Cr.

Enterprise Value

₹ 7098.84 Cr.

No. of Shares

6.43 Cr.

P/E

79.3

P/B

9.24

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  118.75

CASH

₹ 6.27 Cr.

DEBT

₹ 51.72 Cr.

Promoter Holding

-

EPS (TTM)

₹  13.84

Sales Growth

0

ROE

ROCE

Profit Growth

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year19.52%
3 Year2.65%
5 Year5%

Profit Growth

1 Year492.54%
3 Year-13.11%
5 Year14.05%

ROE%

1 Year12.41%
3 Year6.13%
5 Year11.61%

ROCE %

1 Year15.75%
3 Year9.24%
5 Year14.76%

Debt/Equity

0.0679

Price to Cash Flow

47.83

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Investors List
 Share Holding Data is not available for this company.Report us
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 55.55 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of -13.1052664029927% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.64518595561334% for the Past 3 years.
  • Company has a poor ROE of 6.12866666666667% over the past 3 years.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 43.1891.

Quarterly Result (All Figures in Cr.)
 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 531.19 622.86 633.85 563.59 673.61
Total Expenditure 411.8 420.5 528.55 483.49 530.67
Operating Profit 119.39 202.37 105.3 80.09 142.94
Other Income 3.17 9.01 5.65 12.37 19.76
Interest 10.61 6.52 3.07 8.05 7.54
Depreciation 21.16 22.18 25.11 27.62 37.26
Exceptional Items 0 0 0 -64.57 0
Profit Before Tax 90.79 182.67 82.77 -7.78 117.9
Tax 18.27 47.11 21.04 14.88 28.95
Net Profit 72.52 135.56 61.73 -22.66 88.95
Adjusted EPS (Rs.) 13.26 24.79 11.29 -4.14 16.27

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.94 10.94 10.94 10.94 10.94
Total Reserves 486.9 622.42 684.25 661.88 750.2
Borrowings 2.47 1.46 0.73 1.41 1.12
Other N/C liabilities 20.7 25.5 26.42 26.71 26.28
Current liabilities 248.56 181.55 172.15 214.19 298.66
Total Liabilities 769.55 841.87 894.48 915.12 1087.19
Assets
Net Block 229.62 247.58 266.09 265.65 323.82
Capital WIP 28.15 26.73 22.62 73.9 19.36
Intangible WIP 2.35 0 0 0 0
Investments 107.1 122.15 130.17 65.6 42.25
Loans & Advances 8.92 30.57 57.48 123.33 200.93
Other N/C Assets 2.32 2.37 2.51 0.01 2.54
Current Assets 391.1 412.46 415.62 386.62 498.29
Total Assets 769.55 841.87 894.48 915.12 1087.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 90.79 182.67 82.77 -7.78 117.9
Adjustment 33.72 29.13 22.97 91.15 25.36
Changes in Assets & Liabilities 8.68 -11.57 -58.89 25.8 39.29
Tax Paid -24.19 -42.53 -23.34 -15.82 -35.09
Operating Cash Flow 109 157.7 23.51 93.35 147.46
Investing Cash Flow -69.91 -78.99 -33.94 -132.5 -80.8
Financing Cash Flow -42.23 -79.04 14.84 36.53 -62.98
Net Cash Flow -3.14 -0.33 4.41 -2.62 3.67

Corporate Actions

Investors Details

 No Promoters Data available for this company.Report us
 No Investors Data available for this company.Report us

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us
Last Updated on:
Brief about Symbiotec Pharmalab
X